Delineating the predominant GR isoform in the dysplastic region could allow for future isoform-specific targeting that would be critical for BBB functional homeostasis in the dysplastic brain region and better-targeted therapy for patients with drug-resistant epilepsy. The gene discussed is NR3C1; the disease is epilepsy.